Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
-
ARCHIVE Worldwide Sales of Yakult's Irinotecan to Top \150 Bil. in 2005
February 26, 2001
-
ARCHIVE Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
-
ARCHIVE Kyorin, Ono to Codevelop Drug for Urinary Incontinence
February 26, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF
February 26, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF -1-
February 26, 2001
-
ARCHIVE WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
-
ARCHIVE New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF -2-
February 19, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 19, 2001
-
ARCHIVE Boston Scientific Ties Up with Islaeri, Canadian Firms in Cardiac Electrophysiology
February 19, 2001
-
ARCHIVE PMSB to Draft Criteria for Disclosure of Information
February 19, 2001
-
ARCHIVE Takara Shuzo Ties Up with GenCom for Genomic Analysis of ES Cells
February 19, 2001
-
ARCHIVE Mitsubishi Chemical Licenses SPR Technology from Quantech
February 19, 2001
-
ARCHIVE Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
-
ARCHIVE Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
-
ARCHIVE Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
-
ARCHIVE Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
-
ARCHIVE Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…